Infections

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Substance Related Disorders

Behaviors and Mental Disorders

Symptoms and General Pathology

COVID-19

Lung Diseases

Tobacco Use Disorder

Pneumonia

Pneumonia, Viral

Communicable Diseases

Respiratory Tract Infections

Virus Diseases

Coronavirus Infections

Coronaviridae Infections

Nidovirales Infections

RNA Virus Infections

Respiratory Tract Diseases

Substance-Related Disorders

Chemically-Induced Disorders

Mental Disorders

Psychotic Disorders

Analyses of the cohort data will include (1) all patients, or (2) hospitalized patients meeting specific inclusion criteria.

Betsy Rolland, PhD, MLIS, MPH

Michael C Fiore, MD, MPH, MBA

Karen L Conner, MPH

This cohort study will obtain electronic health record (EHR) data (limited data set) from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19 patients to explore whether smoking status, cancer history, and other risk factors among patients diagnosed with COVID-19 are associated with mortality and/or COVID-19 disease severity/complications. Each site will provide data from their health system EHR on a regular basis that includes all patients identified as having COVID-19 at some point in the interval from February 1, 2020, through January 31, 2022.

This cohort study will obtain electronic health record (EHR) data (limited data set) from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19 patients to explore whether smoking status, cancer history, and other risk factors among patients diagnosed with COVID-19 are associated with mortality and/or COVID-19 disease severity/complications. The Cancer Center Cessation Initiative (C3I) is a project launched by the US National Cancer Institute (NCI) to improve the rate at which NCI-designated Cancer Centers provide evidence-based smoking cessation to patients diagnosed with and treated for cancer. The C3I is coordinated at the University of Wisconsin-Center for Tobacco Research and Intervention (UW-CTRI) and the University of Wisconsin Carbone Cancer Center (UWCCC). Twenty-one health systems across the U.S. will provide EHR data to the UW-CTRI coordinating center on all COVID-19 patients identified during the period from February 1, 2020, through January 31, 2022.

Current EHR-based data elements collected will include:

Evidence of COVID-19: ICD-10-CM diagnosis of COVID-19, COVID-19 PCR lab test, and/or COVID-19 antigen lab test

Healthcare system encounter type: inpatient, outpatient, emergency department (ED), urgent care, or other

SES/Demographics variables: insurance status, education, housing status, sex, age, race/ethnicity, height, weight, body mass index

Comorbid diseases: chronic asthma, chronic COPD, chronic bronchiectasis, diabetes mellitus, cardiovascular disease, chronic renal disease, on dialysis, immunocompromised \[due to SLE lupus, rheumatoid arthritis, organ transplant, HIV, Crohn's\], pregnant, cancer (lymphomas, leukemias, lung/respiratory, rectal, breast, prostate, pancreas), hypertension, depression, anxiety, alcohol abuse, pro- clotting disorders, and anti-clotting disorders

Tobacco use variables: smoking status (current, former, never), passive smoke exposure for never smoker, years since quitting (for former smokers), packs smoked per day, years of smoking, pack years, smokeless tobacco user, and marijuana use

Signs and symptoms: temperature, pulse, systolic blood pressure, diastolic blood pressure, oxygen saturation, septic shock, pneumonia, chills, muscle aches/myalgia, rhinorrhea, sore throat, chronic cough, shortness of breath, nausea or vomiting, headache, abdominal pain, diarrhea, dizziness, impaired consciousness, acute cerebrovascular event, ataxia, seizure, taste impairment, smell impairment, vision impairment, nerve pain, and skeletal muscular pain

COVID-19 treatment variables: ICU admission, required supplemental oxygen, intubated for ventilator use, noninvasive positive pressure, and number of days hospitalized

COVID-19 medications including (but not limited to): chloroquine, hydroxychloroquine, tocilizumab, remdesivir, dexamethasone, convalescent plasma, and ascorbic acid

Classes of other medications used: nicotine replacement therapies (NRTs), varenicline medications; blood thinners, steroids, angiotensin converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), short-acting adrenergic bronchodilators, long-acting adrenergic bronchodilators, anticholinergic bronchodilators, bronchodilators combos, inhaled corticosteroids (includes combo medications), and inhaled corticosteroid bronchodilators

Lab tests: COVID-19 PCR test, COVID-19 Antigen test, Albumin, ALT, Bicarbonte, BUN, Calcium, C-Reactive Protein, High Sensitivity, C-Reactive Protein, Creatinine, D-DIMER, ESR, Ferritin, Hematocrit, HgbA1c., INR, LDH, Leukocytes, Platelet Count, Potassium, Procalcitonin, Sodium, Troponin-I, Troponin-T

For the initial paper(s) to be prepared based on these data, the main analytic methods will include GUIDE classification and regression tree models. However, whole sample methods will also be used as complementary analytic methods, which will vary with regard to outcome type: i.e., logistic regression for binary outcomes and Cox proportional hazard analyses for time-to-event outcomes. Initial analyses will focus on hospitalized COVID-19 patients. Later waves of analyses may use different analytic approaches and address different questions.

Participating healthcare systems:

* Duke University (Duke Health)
* Hackensack Meridian Health
* Mayo Clinic
* Memorial Sloan Kettering Cancer Center
* University of Michigan (Michigan Medicine)
* Mount Sinai Health System
* Northwestern University
* New York University (NYU Langone Health)
* University of California Davis (University of California Davis Comprehensive Cancer Center / UC Davis Health)
* University of California San Francisco
* University of North Carolina at Chapel Hill (UNC Health)
* University of Chicago
* University of Illinois at Chicago
* University of Kansas (University of Kansas Medical Center)
* University of Maryland
* University of Utah (University of Utah Health)
* University of Wisconsin (UW Health)
* Vanderbilt University (Vanderbilt University Medical Center)
* Virginia Commonwealth University (VCU Health System/Massey Cancer Center)
* Washington University St Louis
* Yale University (Yale New Haven Hospital)

COVID EHR COHORT at the University of Wisconsin

The Limited data set will be secured, cleaned, harmonized, and undergo initial analyses in mid to late 2022.The existing Data Transfer and Use Agreements (DTUA) negotiated with each 21 participating health systems precludes the University of Wisconsin (UW) from sharing these data with any entity at this time. This was a requirement of the UW IRB prior to transferring the de-identified site data sets to UW. Starting in 2023, investigators desiring access to CEC-UW data will need to apply for access via an NCI contractor organization, Information Management Services (IMS; https://www.imsweb.com/).

In analyses of hospitalized patients, all-cause mortality in patients with COVID-19 illness vs discharge from hospital (binary outcome)

In analyses of hospitalized patients, COVID-19 severity as measured by intubation for respiratory support (i.e., patient required intubation during hospitalization; binary outcome)

National Cancer Institute (NCI)

University of Wisconsin, Madison

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Acquired Immunodeficiency Syndrome

HIV Infections

Immunologic Deficiency Syndromes

Primary Immunodeficiency Diseases

Syndrome

Genetic Diseases, Inborn

All Drugs and Chemicals

Immunosuppressive Agents

Patients with acquired immunodeficiency associated with other immunosuppressive therapy.

Mark Polizzotto, MD

CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function

Study title	NCT ID	Conditions	Eligibility	Organization
COVID EHR COHORT at the University of Wisconsin	NCT04506528	COVID-19 Cancer Nicotine Depend... Pulmonary Disea... Cardiovascular ... Immunosuppressi...	0 Years -	University of Wisconsin, Madison
COVID EHR COHORT at the University of Wisconsin	NCT04506528	COVID-19 Cancer Nicotine Depend... Pulmonary Disea... Cardiovascular ... Immunosuppressi...	0 Years -	University of Wisconsin, Madison
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)	NCT04354818	HIV-1-infection Cancer Primary Immune ... Immunosuppressi... COVID-19	18 Years -	Kirby Institute

Spots Global Cancer Trial Database for immunosuppression disorders